"Neutrality in everything," or "endocrine-metabolic nocturne" of the combined oral contraceptive based on E4/drospirenone: A review

Cover Page

Cite item

Full Text

Abstract

One of the most controversial issues of modern gynecology is the study of the effect of combined oral contraceptives (COCs) on the endocrine-metabolic profile. Unfortunately, there are still hormonophobic prejudices in society about the adverse impact of COCs on body weight, carbohydrate metabolism, and lipid profile despite no evidence base for such judgments. Therefore, the purpose of the article is to analyze the effect of E4/drospirenone-based COCs on endocrine-metabolic parameters through the lens of evidence-based medicine.

About the authors

Mekan R. Orazov

Patrice Lumumba People’s Friendship University of Russia (RUDN University)

Author for correspondence.
Email: omekan@mail.ru
ORCID iD: 0000-0002-5342-8129

D. Sci. (Med.)

Russian Federation, Moscow

Viktor E. Radzinsky

Patrice Lumumba People’s Friendship University of Russia (RUDN University)

Email: omekan@mail.ru
ORCID iD: 0000-0003-4956-0466

D. Sci. (Med.), Prof., Corr. Memb. RAS

Russian Federation, Moscow

Evgeny D. Dolgov

Patrice Lumumba People’s Friendship University of Russia (RUDN University)

Email: omekan@mail.ru
ORCID iD: 0000-0001-6709-5209

Clinical Resident

Russian Federation, Moscow

References

  1. Радзинский В.Е., Оразов М.Р., Долгов Е.Д. Доброкачественная дисплазия молочной железы и масталгия. Комбинированные оральные контрацептивы на основе эстетрола и дроспиренона. Акушерство и гинекология: новости, мнения, обучение. 2025;13(Suppl.):102-8 [Radzinskii VE, Orazov MR, Dolgov ED. Dobrokachestvennaia displaziia molochnoi zhelezy i mastalgiia. Kombinirovannye oral'nye kontratseptivy na osnove estetrola i drospirenona. Akusherstvo i ginekologiia: novosti, mneniia, obuchenie. 2025;13(Suppl.):102-8 (in Russian)]. doi: 10.33029/2303-9698-2025-13-suppl-102-108
  2. Hall KS, Trussell J. Types of combined oral contraceptives used by US women. Contraception. 2012;86(6):659-65. doi: 10.1016/j.contraception.2012.05.017
  3. Metz L, Isacco L, Redman LM. Effect of oral contraceptives on energy balance in women: A review of current knowledge and potential cellular mechanisms. Metabolism. 2022;126:154919. doi: 10.1016/j.metabol.2021.154919
  4. San-Juan-Rodriguez A, Bes-Rastrollo M, Martinez-Gonzalez MA, et al. Oral contraceptives use and development of obesity in a Mediterranean cohort: the SUN (Seguimiento Universidad de Navarra) Project. Int J Obes (Lond). 2020;44(2):320-2. doi: 10.1038/s41366-019-0442-9
  5. Bardaweel SK, Akour AA, Kilani MV. Current knowledge, attitude, and patterns of oral contraceptives utilization among women in Jordan. BMC Womens Health. 2015;15:117. doi: 10.1186/s12905-015-0275-1
  6. Национальные медицинские критерии приемлемости методов контрацепции. 2023. Режим доступа: https://roag-portal.ru/materials. Ссылка активна на 10.10.2024 [Natsional'nye meditsinskie kriterii priemlemosti metodov kontratseptsii. 2023.Available at: https://roag-portal.ru/materials. Accessed: 10.10.2024 (in Russian)].
  7. Schwers J, Eriksson G, Wiqvist N, Diczfalusy E. 15α-hydroxylation: A new pathway of estrogen metabolism in the human fetus and newborn. Biochimica et Biophysica Acta (BBA) – General Subjects. 2003;100(1):313-1. doi: 10.1016/0304-4165(65)90464-2
  8. Schwers J, Govaerts-Videtsky M, Wiqvist N, Diczfalusy E. Metabolism of oestrone sulphate by the previable human foetus. Acta Endocrinol (Copenh). 1965;50(4):597-610. doi: 10.1530/acta.0.0500597
  9. Mancuso S, Benagiano G, Dell'Acqua S, et al. Studies on the metabolism of C-19 steroids in the human foeto-placental unit. 4. Aromatisation and hydroxylation products formed by previable foetuses perfused withandrostenedione and testosterone. Acta Endocrinol (Copenh). 1968;57(2):208-27. doi: 10.1530/acta.0.0570208
  10. Coelingh Bennink F, Holinka CF, Visser M, Coelingh Bennink HJ. Maternal and fetal estetrol levels during pregnancy. Climacteric. 2008;11(Suppl. 1):69-72. doi: 10.1080/13697130802056321
  11. Gérard C, Arnal JF, Jost M, et al. Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. Expert Rev Clin Pharmacol. 2022;15(2):121-37. doi: 10.1080/17512433.2022.2054413
  12. Fruzzetti F, Fidecicchi T, Montt Guevara MM, Simoncini T. Estetrol: A New Choice for Contraception. J Clin Med. 2021;10(23):5625. doi: 10.3390/jcm10235625
  13. Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021;103(4):213-21. doi: 10.1016/j.contraception.2021.01.001
  14. Douxfils J, Gaspard U, Taziaux M, et al. Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women. Climacteric. 2023;26(1):55-63. doi: 10.1080/13697137.2022.2139599
  15. Geraghty P, Taylor HS. The next generation of oral contraception: advances in estrogens. ObGyn Management, June, 2021. Available at: https://cdn.mdedge.com/files/s3fs-public/obgm_the_next_generation_of_oral_contraception_v8.pdf. Accessed: 15.01.2025.
  16. Apter D, Zimmerman Y, Beekman L, et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Health Care. 2017;22(4):260-6. doi: 10.1080/13625187.2017.1336532
  17. Coelingh Bennink HJ, Heegaard AM, Visser M, et al. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric. 2008;11(Suppl. 1):2-14. doi: 10.1080/13697130701798692
  18. De Mello WC, Frohlich ED. Clinical perspectives and fundamental aspects of local cardiovascular and renal Renin-Angiotensin systems. Front Endocrinol (Lausanne). 2014;5:16. doi: 10.3389/fendo.2014.00016
  19. De Mello WC. Chemical Communication between Heart Cells is Disrupted by Intracellular Renin and Angiotensin II: Implications for Heart Development and Disease. Front Endocrinol (Lausanne). 2015;6:72. doi: 10.3389/fendo.2015.00072
  20. Bader M. ACE2, angiotensin-(1–7), and Mas: the other side of the coin. Pflugers Arch – Eur J Physiol. 2012;465(1):79-85. doi: 10.1007/s00424-012-1120-0
  21. Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung. 1985;35(2):459-71.
  22. Pérez-López FR. Clinical experiences with drospirenone: From reproductive to postmenopausal years. Maturitas. 2008;60(2):78-91. doi: 10.1016/j.maturitas.2008.03.009
  23. Оразов М.Р., Ермаков В.В., Новгинов Д.С. Влияние контрацептива, содержащего эстетрол/дроспиренон, на сексуальную функцию женщин репродуктивного возраста. Гинекология. 2023;25(1):102-5 [Orazov MR, Ermakov VV, Novginov DS. Effect of an estetrol/drospirenone contraceptive on sexual function in women of reproductive age. Gynecology. 2023;25(1):102-5 (in Russian)]. doi: 10.26442/20795696.2023.1.202033
  24. Оразов М.Р., Радзинский В.Е., Долгов Е.Д., Ермаков В.В. Эндокринно-метаболические эффекты оральных контрацептивов, содержащих эстетрол и дроспиренон. Вопросы гинекологии, акушерства и перинатологии. 2022;21(4):146-50 [Orazov MR, Radzinskii VE, Dolgov ED, Ermakov VV. Endokrinno-metabolicheskie effekty oral'nykh kontratseptivov, soderzhashchikh estetrol i drospirenon. Voprosy ginekologii, akusherstva i perinatologii. 2022;21(4):146-50 (in Russian)]. doi: 10.20953/1726-1678-2022-4-146-150
  25. Оразов М.Р., Радзинский В.Е., Долгов Е.Д., Ермаков В.В. Риски венозных тромбоэмболий при использовании гормональных контрацептивов, содержащих эстетрол и дроспиренон. Вопросы гинекологии, акушерства и перинатологии. 2022;21(6):125-30 [Orazov MR, Radzinskii VE, Dolgov ED, Ermakov VV. Riski venoznykh tromboembolii pri ispol'zovanii gormonal'nykh kontratseptivov, soderzhashchikh estetrol i drospirenon. Voprosy ginekologii, akusherstva i perinatologii. 2022;21(6):125-30 (in Russian)]. doi: 10.20953/1726-1678-2022-6-125-130

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).